CAMBRIDGE, Mass., Nov. 3, 2010 /PRNewswire/ -- The DNA Medicine Institute, a biomedical research organization whose mission is to advance patient care, alleviate human suffering, and treat disease through innovation, has received a $222,999 grant from the U.S. government under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the development of its Universal Blood Sensor. The QTDP grant program, established as a result of the Patient Protection and Affordable Care Act of 2010, targeted projects that show potential to result in new therapies to treat areas of unmet medical need or prevent, detect or treat chronic or acute diseases and conditions, reduce long-term health care costs in the United States, or significantly advance the goal of curing cancer within the next 30 years. Allocation of the credit also took into consideration which projects show the greatest potential to create and sustain high-quality, high-paying U.S. jobs and to advance U.S. competitiveness in life, biological and medical sciences.
DMI's Universal Blood Sensor offers a full system's check of a person anywhere, anytime, and with a single drop of blood—all without the use of a hospital-sized testing center, a phlebotomist, and skilled medical practitioners. The sensor allows for all disease states from all organs to be analyzed, whether this involves the heart, blood, lungs, brain, kidneys, cancer, or infection. Real-time decision analysis allows the user to proceed with optimal management in the event of an abnormal state.
Eugene Chan, M.D., President and Chief Scientific Officer of the DNA Medicine Institute, commented: "This funding will allow us to speed the development of innovations for making vital diagnostic information readily available to all patients regardless of their setting, need, or economic condition."
About DNA Medicine Institute
DMI utilizes an interdisciplinary, multi-faceted approach to in